Abbott Laboratories (ABT) Falls 3.45% for December 21

Equities Staff |

One of the S&P 500’s big losers for Monday December 21 was Abbott Laboratories (ABT). The company’s stock fell 3.45% to $43.70 on volume of 13.04 million shares.

The stock opened the day at 44.96 and traded between a low of $43.70 and a high of $45.04. The stock finished the day down $1.56 per share. Abbott Laboratories has an average daily volume of 7.17 million and a total float of 1.49 billion shares. The 50-day SMA for Abbott Laboratories is $44.41 and its 200-day SMA is $46.20. The high for the stock over the last 52 weeks is $51.74 and the low is $39.00.

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott Laboratories is centered in Abbott Park, IL, and has 77,000 employees. Today’s trading day leaves the company with a market cap of $65.19 billionwith a P/E Ratio of 14.6. The company has a P/S ratio of 3.29, P/B ratio of 3.09, and a 25.1.

For a complete fundamental analysis analysis of Abbott Laboratories, check out’s Stock Valuation Analysis report for ABT. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…